Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - glucose monohydrate, quantity: 25 g/l; calcium chloride dihydrate, quantity: 0.184 g/l; magnesium chloride hexahydrate, quantity: 51 mg/l; sodium chloride, quantity: 5.38 g/l; sodium bicarbonate, quantity: 2.1 g/l; sodium lactate, quantity: 1.68 g/l - solution, irrigation - excipient ingredients: water for injections - physioneal 40 is indicated for use in peritoneal dialysis in patients with acute or chronic renal failure.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - glucose monohydrate, quantity: 15 g/l; calcium chloride dihydrate, quantity: 0.184 g/l; magnesium chloride hexahydrate, quantity: 51 mg/l; sodium chloride, quantity: 5.38 g/l; sodium bicarbonate, quantity: 2.1 g/l; sodium lactate, quantity: 1.68 g/l - solution, irrigation - excipient ingredients: water for injections - physioneal 40 is indicated for use in peritoneal dialysis in patients with acute or chronic renal failure.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sodium nitroprusside, quantity: 50 mg - injection, solution - excipient ingredients: water for injections - dbl? sodium nitroprusside injection is indicated for:,1. immediate reduction of blood pressure in patients with hypertensive crises. concomitant oral antihypertensive medication should be started while the hypertensive emergency is being brought under control with sodium nitroprusside.,2. producing controlled hypotension during anaesthesia in order to reduce bleeding in surgical procedures where surgeon and anaesthetist deem it appropriate.,3. short term therapy of cardiac failure, to enhance cardiac output and lower myocardial oxygen requirements. patients should be commenced on oral therapy as soon as possible.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - glucose monohydrate, quantity: 42.5 g/l (equivalent: glucose, qty 38.6 g/l); sodium chloride, quantity: 5.38 g/l; magnesium chloride hexahydrate, quantity: 51 mg/l; calcium chloride dihydrate, quantity: 0.184 g/l; sodium bicarbonate, quantity: 2.1 g/l; sodium lactate, quantity: 1.68 g/l - solution, dialysis - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - physioneal 40 is indicated for use in peritoneal dialysis in patients with acute or chronic renal failure.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - glucose, quantity: 50 g/l - injection, solution - excipient ingredients: water for injections - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code)

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - glucose, quantity: 45 g (equivalent: glucose monohydrate, qty 50 g) - injection - excipient ingredients: water for injections - glucose (5%) intravenous infusions are mainly indicated: - whenever non-electrolyte fluid replacement is required. - as a vehicle for drug delivery, provided that the added components are compatible with glucose.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - glucose, quantity: 22.5 g (equivalent: glucose monohydrate, qty 25 g) - injection - excipient ingredients: water for injections - glucose (5%) intravenous infusions are mainly indicated: - whenever non-electrolyte fluid replacement is required. - as a vehicle for drug delivery, provided that the added components are compatible with glucose.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - glucose, quantity: 11.25 g (equivalent: glucose monohydrate, qty 12.5 g) - injection - excipient ingredients: water for injections - glucose (5%) intravenous infusions are mainly indicated: - whenever non-electrolyte fluid replacement is required. - as a vehicle for drug delivery, provided that the added components are compatible with glucose.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - water for injections, quantity: 3 ml - injection, diluent for - excipient ingredients: - berinert iv is indicated for the treatment of acute attacks in patients with hereditary angioedema (hae).

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - water for injections, quantity: 0.5 ml - injection, solution - excipient ingredients: - revestive is indicated for the treatment of adult and paediatric patients 2 years of age and above with short bowel syndrome (sbs) who are dependent on parenteral support.,patients should be stable for at least 4 weeks on their parenteral support regimen before initiating teduglutide therapy